Targeting JAK‐1 in Disseminated Cutaneous Lichen Planus
ABSTRACT We report the case of a 63‐year‐old woman with an exuberant and recalcitrant clinical presentation of LP who had an excellent response to 200 mg/day abrocitinib, a JAK‐1 inhibitor, after failure to other commonly used therapies. The efficacy of JAK inhibitors in lichen planus is supported by small case series and isolated case reports. Further studies are necessary to confirm their full potential.
Authors
- Lara de Melo Siems
- Artur Antônio Duarte (ORCID: https://orcid.org/0000-0003-0361-9776)
- Dimitri Luz
- Flávio Henrique Ferreira Barbosa
Institutions
- Universidade de Santo Amaro (BR)
Publication Details
- Journal
- JEADV Clinical Practice
- Published
- 2025-05-04
- DOI
- https://doi.org/10.1002/jvc2.70054
- Citations
- 1
- Primary Topic
- Oral Health Pathology and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47